Anti-neutrophil cytoplasmic antibodies (ANCA) are mainly associated with medium and small vessel vasculitis. Two main methodologies currently available for detection of these antibodies are indirect immunofluorescence (IIF) and monospecific proteinase 3 (PR3) and myeloperoxidase (MPO) based immunoassays. However, well-defined guidelines regarding mode of testing for ANCA in laboratories still don't exist, leading to problems in diagnosis and further patient management. Anti-neutrophil cytoplasmic antibodies testing by IIF and enzyme linked immunosorbent assay (ELISA) often pose a significant challenge in diseases other than vasculitis and in overlapping autoimmune conditions. Anti-neutrophil cytoplasmic antibodies reporting by IIF can be challenging in certain circumstances. This case series aims to discuss four cases with probable interference of anti-nuclear antibodies (ANA) during ANCA testing by IIF resulting in ANCA false positivity. All four cases on subsequent reflex testing by line immunoassay (LIA) for PR3, MPO and glomerular basement membrane (GBM) antigens proved otherwise. While analysing for the presence of ANCA by IIF, the possible interference of ANA leading to a false positive ANCA result should be kept in mind and alternative methods of testing like ELISA, extended granulocyte based IIF assays with MPO and PR3 coated beads, etc., should also be advised. Probability of atypical ANCA in diseases other than vasculitis should also be considered in case of ambiguous results.
{"title":"Interference of anti-nuclear antibodies on determination of anti-neutrophil cytoplasmic antibodies in patients suspected of vasculitis: a case series.","authors":"Mala Mahto, Neha Rai, Pulak Ranjan Das, Saurabh Karmakar, Divendu Bhushan","doi":"10.11613/BM.2023.031001","DOIUrl":"10.11613/BM.2023.031001","url":null,"abstract":"<p><p>Anti-neutrophil cytoplasmic antibodies (ANCA) are mainly associated with medium and small vessel vasculitis. Two main methodologies currently available for detection of these antibodies are indirect immunofluorescence (IIF) and monospecific proteinase 3 (PR3) and myeloperoxidase (MPO) based immunoassays. However, well-defined guidelines regarding mode of testing for ANCA in laboratories still don't exist, leading to problems in diagnosis and further patient management. Anti-neutrophil cytoplasmic antibodies testing by IIF and enzyme linked immunosorbent assay (ELISA) often pose a significant challenge in diseases other than vasculitis and in overlapping autoimmune conditions. Anti-neutrophil cytoplasmic antibodies reporting by IIF can be challenging in certain circumstances. This case series aims to discuss four cases with probable interference of anti-nuclear antibodies (ANA) during ANCA testing by IIF resulting in ANCA false positivity. All four cases on subsequent reflex testing by line immunoassay (LIA) for PR3, MPO and glomerular basement membrane (GBM) antigens proved otherwise. While analysing for the presence of ANCA by IIF, the possible interference of ANA leading to a false positive ANCA result should be kept in mind and alternative methods of testing like ELISA, extended granulocyte based IIF assays with MPO and PR3 coated beads, <i>etc</i>., should also be advised. Probability of atypical ANCA in diseases other than vasculitis should also be considered in case of ambiguous results.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"33 3","pages":"031001"},"PeriodicalIF":3.3,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9954831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The analysis of blood alcohol concentration (BAC), a pivotal toxicological test, concerns acute alcohol intoxication (AAI) and driving under the influence (DUI). As such, BAC presents an organizational challenge for clinical laboratories, with unique complexities due to the need for forensic defensibility as part of the diagnostic process. Unfortunately, a significant number of scientific investigations dealing with the subject present discrepancies that make it difficult to identify optimal practices in sample collection, transportation, handling, and preparation. This review provides a systematic analysis of the preanalytical phase of BAC that aims to identify and explain the chemical, physiological, and pharmacological mechanisms underlying controllable operational factors. Nevertheless, it seeks evidence for the necessity to separate preanalytical processes for diagnostic and forensic BAC testing. In this regard, the main finding of this review is that no literature evidence supports the necessity to differentiate preanalytical procedures for AAI and DUI, except for the traceability throughout the chain of custody. In fact, adhering to correct preanalytical procedures provided by official bodies such as European federation of clinical chemistry and laboratory medicine for routine phlebotomy ensures both diagnostic accuracy and forensic defensibility of BAC. This is shown to depend on the capability of modern pre-evacuated sterile collection tubes to control major factors influencing BAC, namely non-enzymatic oxidation and microbial contamination. While certain restrictions become obsolete with such devices, as the use of sodium fluoride (NaF) for specific preservation of forensic BAC, this review reinforces the recommendation to use non-alcoholic disinfectants as a means to achieve “error-proof” procedures in challenging operational environments like the emergency department.
血液酒精浓度(BAC)分析是一项关键的毒理学测试,涉及急性酒精中毒(AAI)和酒后驾驶(DUI)。因此,BAC对临床实验室提出了组织上的挑战,由于需要作为诊断过程的一部分的法医防御能力,BAC具有独特的复杂性。不幸的是,大量涉及该主题的科学调查存在差异,这使得很难确定样品收集,运输,处理和制备的最佳实践。这篇综述提供了对BAC分析前阶段的系统分析,旨在识别和解释可控操作因素背后的化学、生理和药理学机制。尽管如此,它寻求证据的必要性,以分离诊断和法医BAC测试的分析前过程。在这方面,本综述的主要发现是,除了整个监管链的可追溯性外,没有文献证据支持区分AAI和DUI的分析前程序的必要性。事实上,按照欧洲临床化学和检验医学联合会(European federation of clinical chemistry and laboratory medicine)等官方机构提供的正确分析前程序进行常规放血,既能保证BAC的诊断准确性,又能保证BAC的法医辩护能力。这取决于现代预抽真空无菌收集管控制影响BAC的主要因素的能力,即非酶氧化和微生物污染。虽然此类设备的某些限制已经过时,例如使用氟化钠(NaF)来特定保存法医BAC,但本综述强化了使用非酒精消毒剂作为在急诊科等具有挑战性的操作环境中实现“防错”程序的建议。
{"title":"Blood alcohol concentration in the clinical laboratory: a narrative review of the preanalytical phase in diagnostic and forensic testing","authors":"Cristiano Ialongo","doi":"10.11613/bm.2024.010501","DOIUrl":"https://doi.org/10.11613/bm.2024.010501","url":null,"abstract":"The analysis of blood alcohol concentration (BAC), a pivotal toxicological test, concerns acute alcohol intoxication (AAI) and driving under the influence (DUI). As such, BAC presents an organizational challenge for clinical laboratories, with unique complexities due to the need for forensic defensibility as part of the diagnostic process. Unfortunately, a significant number of scientific investigations dealing with the subject present discrepancies that make it difficult to identify optimal practices in sample collection, transportation, handling, and preparation. This review provides a systematic analysis of the preanalytical phase of BAC that aims to identify and explain the chemical, physiological, and pharmacological mechanisms underlying controllable operational factors. Nevertheless, it seeks evidence for the necessity to separate preanalytical processes for diagnostic and forensic BAC testing. In this regard, the main finding of this review is that no literature evidence supports the necessity to differentiate preanalytical procedures for AAI and DUI, except for the traceability throughout the chain of custody. In fact, adhering to correct preanalytical procedures provided by official bodies such as European federation of clinical chemistry and laboratory medicine for routine phlebotomy ensures both diagnostic accuracy and forensic defensibility of BAC. This is shown to depend on the capability of modern pre-evacuated sterile collection tubes to control major factors influencing BAC, namely non-enzymatic oxidation and microbial contamination. While certain restrictions become obsolete with such devices, as the use of sodium fluoride (NaF) for specific preservation of forensic BAC, this review reinforces the recommendation to use non-alcoholic disinfectants as a means to achieve “error-proof” procedures in challenging operational environments like the emergency department.","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"23 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138541579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jasmina Katanić, Bojan Stanimirov, Vanesa Sekeruš, Maja Đanić, Nebojša Pavlović, Momir Mikov, Karmen Stankov
Clinical laboratory practice represents an essential part of clinical decision-making, as it influences 60-70% of medical decisions at all levels of health care. Results of biochemical laboratory tests (BLTs) have a key role in establishment of adequate diagnosis as well as in evaluation of treatment progress and outcome. The prevalence of drug-laboratory test interactions (DLTIs) is up to 43% of patients who had laboratory results influenced by drugs. Unrecognized DLTIs may lead to misinterpreted BLTs results, incorrect or delayed diagnosis, extra costs for unnecessary additional tests or inadequate therapy, as all may cause false clinical decisions. The significance of timely and adequate recognition of DLTIs is to prevent common clinical consequences such as incorrectly interpreted test results, delayed or non-treated condition due to erroneous diagnosis or unnecessary extra tests or therapy. Medical professionals should be educated that it is essential to obtain patient data about medications especially for the drugs used in the last 10 days before biological material collection. Our mini-review aims to provide a comprehensive overview of the current state in this important domain of medical biochemistry with detailed analysis of the effect of drugs on BLTs and to give detailed information to medical specialists.
{"title":"Drug interference with biochemical laboratory tests.","authors":"Jasmina Katanić, Bojan Stanimirov, Vanesa Sekeruš, Maja Đanić, Nebojša Pavlović, Momir Mikov, Karmen Stankov","doi":"10.11613/BM.2023.020601","DOIUrl":"https://doi.org/10.11613/BM.2023.020601","url":null,"abstract":"<p><p>Clinical laboratory practice represents an essential part of clinical decision-making, as it influences 60-70% of medical decisions at all levels of health care. Results of biochemical laboratory tests (BLTs) have a key role in establishment of adequate diagnosis as well as in evaluation of treatment progress and outcome. The prevalence of drug-laboratory test interactions (DLTIs) is up to 43% of patients who had laboratory results influenced by drugs. Unrecognized DLTIs may lead to misinterpreted BLTs results, incorrect or delayed diagnosis, extra costs for unnecessary additional tests or inadequate therapy, as all may cause false clinical decisions. The significance of timely and adequate recognition of DLTIs is to prevent common clinical consequences such as incorrectly interpreted test results, delayed or non-treated condition due to erroneous diagnosis or unnecessary extra tests or therapy. Medical professionals should be educated that it is essential to obtain patient data about medications especially for the drugs used in the last 10 days before biological material collection. Our mini-review aims to provide a comprehensive overview of the current state in this important domain of medical biochemistry with detailed analysis of the effect of drugs on BLTs and to give detailed information to medical specialists.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"33 2","pages":"020601"},"PeriodicalIF":3.3,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Silvia F Benozzi, Gisela Unger, Amparo Campion, Pablo G Milano, Graciela L Pennacchiotti
Introduction: Although current guidelines recommend not drinking coffee prior to phlebotomy, our hypothesis is that drinking coffee does not affect the clinical interpretation of biochemical and haematological test results.
Materials and methods: Twenty-seven volunteers were studied in basal state (T0) and 1h after (T1) drinking coffee. Routine haematological (Sysmex-XN1000 analyser) and biochemistry parameters (Vitros 4600 analyser) were studied. Results were compared using the Wilcoxon test (P < 0.05). A clinical change was considered when mean percent difference (MD%) was higher than the reference change value (RCV).
Results: Coffee intake produced statistically, but not clinically, significant: i) increases in haemoglobin (P = 0.009), mean cell haemoglobin concentration (P = 0.044), neutrophils (P = 0.001), albumin (P = 0.001), total protein (P = 0.000), cholesterol (P = 0.025), high density lipoprotein cholesterol (P = 0.007), uric acid (P = 0.011), calcium (P = 0.001), potassium (P = 0.010), aspartate aminotransferase (P = 0.001), amylase (P = 0.026), and lactate dehydrogenase (P = 0.001), and ii) decreases in mean cell volume (P = 0.002), red cell distribution width (P = 0.001), eosinophils (P = 0.002), and lymphocytes (P = 0.001), creatinine (P = 0.001), total bilirubin (P = 0.012), phosphorus (P = 0.001), magnesium (P = 0.007), and chloride (P = 0.001).
Conclusion: Drinking a cup of coffee 1 hour prior to phlebotomy produces no clinically significant changes in routine biochemical and haematological test results.
{"title":"Coffee intake one hour prior to phlebotomy produces no clinically significant changes in routine biochemical test results.","authors":"Silvia F Benozzi, Gisela Unger, Amparo Campion, Pablo G Milano, Graciela L Pennacchiotti","doi":"10.11613/BM.2023.020705","DOIUrl":"https://doi.org/10.11613/BM.2023.020705","url":null,"abstract":"<p><strong>Introduction: </strong>Although current guidelines recommend not drinking coffee prior to phlebotomy, our hypothesis is that drinking coffee does not affect the clinical interpretation of biochemical and haematological test results.</p><p><strong>Materials and methods: </strong>Twenty-seven volunteers were studied in basal state (T0) and 1h after (T1) drinking coffee. Routine haematological (Sysmex-XN1000 analyser) and biochemistry parameters (Vitros 4600 analyser) were studied. Results were compared using the Wilcoxon test (P < 0.05). A clinical change was considered when mean percent difference (MD%) was higher than the reference change value (RCV).</p><p><strong>Results: </strong>Coffee intake produced statistically, but not clinically, significant: i) increases in haemoglobin (P = 0.009), mean cell haemoglobin concentration (P = 0.044), neutrophils (P = 0.001), albumin (P = 0.001), total protein (P = 0.000), cholesterol (P = 0.025), high density lipoprotein cholesterol (P = 0.007), uric acid (P = 0.011), calcium (P = 0.001), potassium (P = 0.010), aspartate aminotransferase (P = 0.001), amylase (P = 0.026), and lactate dehydrogenase (P = 0.001), and ii) decreases in mean cell volume (P = 0.002), red cell distribution width (P = 0.001), eosinophils (P = 0.002), and lymphocytes (P = 0.001), creatinine (P = 0.001), total bilirubin (P = 0.012), phosphorus (P = 0.001), magnesium (P = 0.007), and chloride (P = 0.001).</p><p><strong>Conclusion: </strong>Drinking a cup of coffee 1 hour prior to phlebotomy produces no clinically significant changes in routine biochemical and haematological test results.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"33 2","pages":"020705"},"PeriodicalIF":3.3,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9647589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Renal tubular acidosis (RTA) is a rare disorder that can be inherited or acquired, and results in an inability of the kidneys to maintain normal acid-base balance. We present a case of recurrent, severe hypokalaemia and rhabdomyolysis in a young woman who had an associated normal anion gap metabolic acidosis and was subsequently diagnosed with distal RTA associated with Hashimoto's thyroiditis. Distal RTA associated with Hashimoto's thyroiditis is rare and probably develops because of autoimmune-mediated mechanisms, causing an inability of the H+-ATPase pump in alpha-intercalated cells of the cortical collecting duct to secrete H+, with subsequent failure of urinary acidification. In this case, this hypothesis was supported by the exclusion of common genetic mutations associated with distal RTA. We illustrate that utilizing a systematic, physiology-based approach for challenging electrolyte and acid-base disorders enables identification of the root cause and underlying disease mechanisms.
{"title":"Distal renal tubular acidosis in a patient with Hashimoto's thyroiditis: a case report.","authors":"Nontembiso Mhlana, Marizna Korf, Mogamat Razeen Davids, Mogamat-Yazied Chothia","doi":"10.11613/BM.2023.020802","DOIUrl":"https://doi.org/10.11613/BM.2023.020802","url":null,"abstract":"<p><p>Renal tubular acidosis (RTA) is a rare disorder that can be inherited or acquired, and results in an inability of the kidneys to maintain normal acid-base balance. We present a case of recurrent, severe hypokalaemia and rhabdomyolysis in a young woman who had an associated normal anion gap metabolic acidosis and was subsequently diagnosed with distal RTA associated with Hashimoto's thyroiditis. Distal RTA associated with Hashimoto's thyroiditis is rare and probably develops because of autoimmune-mediated mechanisms, causing an inability of the H<sup>+</sup>-ATPase pump in alpha-intercalated cells of the cortical collecting duct to secrete H<sup>+</sup>, with subsequent failure of urinary acidification. In this case, this hypothesis was supported by the exclusion of common genetic mutations associated with distal RTA. We illustrate that utilizing a systematic, physiology-based approach for challenging electrolyte and acid-base disorders enables identification of the root cause and underlying disease mechanisms.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"33 2","pages":"020802"},"PeriodicalIF":3.3,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9647590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ruth Cano-Corres, Gemma Sole-Enrech, Maria Isabel Aparicio-Calvente
Introduction: Icterus, if not detected, can affect the validity of results delivered by clinical laboratories, leading to erroneous results. This study aims to define bilirubin interference for some biochemical analytes and compare it with the manufacturer's data.
Material and methods: Serum pools prepared with outpatients' samples were spiked with increasing bilirubin concentration (Merck, reference14370, Darmstadt, Germany) up to 513 µmol/L in order to evaluate the bias for the following biochemical analytes: creatinine (CREA), creatine kinase (CK), cholesterol (CHOL), gamma-glutamyltransferase (GGT), high-density lipoprotein cholesterol (HDL), and total protein (TP). For each analyte, six pools of different concentrations were prepared. Measurements were made employing Cobas 8000 analyser c702-502, Roche Diagnostics (Mannheim, Germany). This study employed a study procedure defined by the Spanish Society of Laboratory Medicine.
Results: Obtained bilirubin concentrations producing a negative interference were 103 µmol/L for CHOL, 205 µmol/L for TP and 410 µmol/L for CK, but only for CK values less than 100 U/L. Bilirubin concentrations lower than 513 µmol/L do not produce interference for HDL and GGT. Finally, for the studied bilirubin concentrations, there is no interference for CREA higher than 80 µmol/L.
Conclusion: Icterus interferences have been defined for each analyte, observing differences compared to data provided by the manufacturer. The evidence indicates that each laboratory should evaluate icteric interferences to ensure the high quality of the delivered results, thus benefiting patient care.
{"title":"Definition of icteric interference index for six biochemical analytes.","authors":"Ruth Cano-Corres, Gemma Sole-Enrech, Maria Isabel Aparicio-Calvente","doi":"10.11613/BM.2023.020702","DOIUrl":"https://doi.org/10.11613/BM.2023.020702","url":null,"abstract":"<p><strong>Introduction: </strong>Icterus, if not detected, can affect the validity of results delivered by clinical laboratories, leading to erroneous results. This study aims to define bilirubin interference for some biochemical analytes and compare it with the manufacturer's data.</p><p><strong>Material and methods: </strong>Serum pools prepared with outpatients' samples were spiked with increasing bilirubin concentration (Merck, reference14370, Darmstadt, Germany) up to 513 µmol/L in order to evaluate the bias for the following biochemical analytes: creatinine (CREA), creatine kinase (CK), cholesterol (CHOL), gamma-glutamyltransferase (GGT), high-density lipoprotein cholesterol (HDL), and total protein (TP). For each analyte, six pools of different concentrations were prepared. Measurements were made employing Cobas 8000 analyser c702-502, Roche Diagnostics (Mannheim, Germany). This study employed a study procedure defined by the Spanish Society of Laboratory Medicine.</p><p><strong>Results: </strong>Obtained bilirubin concentrations producing a negative interference were 103 µmol/L for CHOL, 205 µmol/L for TP and 410 µmol/L for CK, but only for CK values less than 100 U/L. Bilirubin concentrations lower than 513 µmol/L do not produce interference for HDL and GGT. Finally, for the studied bilirubin concentrations, there is no interference for CREA higher than 80 µmol/L.</p><p><strong>Conclusion: </strong>Icterus interferences have been defined for each analyte, observing differences compared to data provided by the manufacturer. The evidence indicates that each laboratory should evaluate icteric interferences to ensure the high quality of the delivered results, thus benefiting patient care.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"33 2","pages":"020702"},"PeriodicalIF":3.3,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9653340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: COVID-19 and vaccination may affect some parameters of the complete blood count (CBC). The aim of this study was to determine reference intervals (RI) of CBC in healthy population with different COVID-19 and vaccination backgrounds and compare them with those established previously.
Materials and methods: A cross-sectional study was conducted in donors who attended the Traumatology Hospital "Dr. Victorio de la Fuente Narváez" (HTVFN) from June to September 2021. Reference intervals were established using the non-parametric method on Sysmex XN-1000. For differences between groups with different COVID-19 and vaccination backgrounds, non-parametric tests were used.
Results: The RI were established in 156 men and 128 women. Haemoglobin (Hb), haematocrit (Hct), red blood cells (RBC), platelets (Plt), mean platelets volume (MPV), monocytes and relative neutrophils were higher in men than women (P < 0.001). The percentiles of Hb, Hct, RBC, MPV and relative monocytes showed higher values; Plt, white blood cells (WBC), lymphocytes, monocytes, neutrophils, eosinophils and absolute basophils, the 2.5th was higher and the 97.5th was lower; for lymphocytes and relative neutrophils, both percentiles had a trend toward lower values, compared to previous RI. Differences between groups with different COVID-19 and vaccination backgrounds, in lymphocytes (P = 0.038), neutrophils (P = 0.017) and eosinophils (P = 0.018) in men; Hct (P = 0.014), RDW (P = 0.023) in women and MPV (P = 0.001) in both, were not considered pathological.
Conclusions: The RI for the CBC were established in a Mestizo-Mexican population with different COVID-19 and vaccination backgrounds, so should be updated and validated in different hospitals close to the HTVFN that use the same analyser.
{"title":"Establishment of reference intervals for complete blood count in times of COVID-19 and vaccination.","authors":"Claudia Mendieta-Gutiérrez, Selene Chávez-González, Brenda Ivonne Rodríguez-Romero, Jazmín Anahí Sánchez-Garrido, Arturo Figueroa-Gómez, Jesús Bernabé Licona-Vela, Arturo Cuauhtémoc Juárez-Pérez, Alejandro Cabello-López, Guadalupe Aguilar-Madrid, Carmina Jiménez-Ramírez","doi":"10.11613/BM.2023.020701","DOIUrl":"https://doi.org/10.11613/BM.2023.020701","url":null,"abstract":"<p><strong>Introduction: </strong>COVID-19 and vaccination may affect some parameters of the complete blood count (CBC). The aim of this study was to determine reference intervals (RI) of CBC in healthy population with different COVID-19 and vaccination backgrounds and compare them with those established previously.</p><p><strong>Materials and methods: </strong>A cross-sectional study was conducted in donors who attended the Traumatology Hospital \"Dr. Victorio de la Fuente Narváez\" (HTVFN) from June to September 2021. Reference intervals were established using the non-parametric method on Sysmex XN-1000. For differences between groups with different COVID-19 and vaccination backgrounds, non-parametric tests were used.</p><p><strong>Results: </strong>The RI were established in 156 men and 128 women. Haemoglobin (Hb), haematocrit (Hct), red blood cells (RBC), platelets (Plt), mean platelets volume (MPV), monocytes and relative neutrophils were higher in men than women (P < 0.001). The percentiles of Hb, Hct, RBC, MPV and relative monocytes showed higher values; Plt, white blood cells (WBC), lymphocytes, monocytes, neutrophils, eosinophils and absolute basophils, the 2.5th was higher and the 97.5th was lower; for lymphocytes and relative neutrophils, both percentiles had a trend toward lower values, compared to previous RI. Differences between groups with different COVID-19 and vaccination backgrounds, in lymphocytes (P = 0.038), neutrophils (P = 0.017) and eosinophils (P = 0.018) in men; Hct (P = 0.014), RDW (P = 0.023) in women and MPV (P = 0.001) in both, were not considered pathological.</p><p><strong>Conclusions: </strong>The RI for the CBC were established in a Mestizo-Mexican population with different COVID-19 and vaccination backgrounds, so should be updated and validated in different hospitals close to the HTVFN that use the same analyser.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"33 2","pages":"020701"},"PeriodicalIF":3.3,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adriana Bokulić, Ivana Zec, Domagoj Marijančević, Sanja Goreta
Introduction: Immunoassays are the most common method in routine practice for measuring androgens in women. Study's aim was to establish new population specific indirect reference intervals (RI) for dehydroepiandrostenedione sulphate (DHEAS) and for new androstenedione test available on automated Roche Cobas electrochemiluminescent immunoassay method.
Materials and methods: From extracted laboratory records, testosterone, sex hormone binding globulin and follicle-stimulating hormone were used as reference tests to exclude possibly diseased women. After the data selection steps, the study included 3500 subjects for DHEAS and 520 for androstenedione aged 20-45 years. To evaluate the need for age partitioning, we calculated standard deviation ratio and bias ratio. For each hormone, 90% and 95% RIs were calculated with appropriate statistical method.
Results: Total age group (20-45 years) 95% RIs were: 2.77-11.50 µmol/L for DHEAS and 2.48-8.89 nmol/L for androstenedione. Age-stratified 95% RIs for DHEAS were: 3.65-12.76 µmol/L (20-25 years); 2.97-11.50 µmol/L (25-35 years) and 2.30-9.83 µmol/L (35-45 years). Age-stratified 95% RIs for androstenedione were: 3.02-9.43 nmol/L (20-30 years) and 2.23-7.75 nmol/L (30-45 years).
Conclusion: New RIs for DHEAS were slightly wider for age group 20-25 and 35-45, while the differences in the age group 25-35 years were more pronounced. Androstenedione RI showed significantly higher concentrations than the manufacturer's. Age-related decrease of androgens should be considered when calculating RIs. We propose population specific, age-stratified RIs for DHEAS and androstenedione on electrochemiluminescent method, which should improve test interpretation in women of reproductive age.
{"title":"Androgens in women: Establishing reference intervals for dehydroepiandrostenedione sulphate and androstenedione on the Roche Cobas.","authors":"Adriana Bokulić, Ivana Zec, Domagoj Marijančević, Sanja Goreta","doi":"10.11613/BM.2023.020706","DOIUrl":"https://doi.org/10.11613/BM.2023.020706","url":null,"abstract":"<p><strong>Introduction: </strong>Immunoassays are the most common method in routine practice for measuring androgens in women. Study's aim was to establish new population specific indirect reference intervals (RI) for dehydroepiandrostenedione sulphate (DHEAS) and for new androstenedione test available on automated Roche Cobas electrochemiluminescent immunoassay method.</p><p><strong>Materials and methods: </strong>From extracted laboratory records, testosterone, sex hormone binding globulin and follicle-stimulating hormone were used as reference tests to exclude possibly diseased women. After the data selection steps, the study included 3500 subjects for DHEAS and 520 for androstenedione aged 20-45 years. To evaluate the need for age partitioning, we calculated standard deviation ratio and bias ratio. For each hormone, 90% and 95% RIs were calculated with appropriate statistical method.</p><p><strong>Results: </strong>Total age group (20-45 years) 95% RIs were: 2.77-11.50 µmol/L for DHEAS and 2.48-8.89 nmol/L for androstenedione. Age-stratified 95% RIs for DHEAS were: 3.65-12.76 µmol/L (20-25 years); 2.97-11.50 µmol/L (25-35 years) and 2.30-9.83 µmol/L (35-45 years). Age-stratified 95% RIs for androstenedione were: 3.02-9.43 nmol/L (20-30 years) and 2.23-7.75 nmol/L (30-45 years).</p><p><strong>Conclusion: </strong>New RIs for DHEAS were slightly wider for age group 20-25 and 35-45, while the differences in the age group 25-35 years were more pronounced. Androstenedione RI showed significantly higher concentrations than the manufacturer's. Age-related decrease of androgens should be considered when calculating RIs. We propose population specific, age-stratified RIs for DHEAS and androstenedione on electrochemiluminescent method, which should improve test interpretation in women of reproductive age.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"33 2","pages":"020706"},"PeriodicalIF":3.3,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9653339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marko Lucijanic, Ivan Krecak, Ena Soric, Anica Sabljic, Davor Galusic, Hrvoje Holik, Vlatka Perisa, Martina Moric Peric, Ivan Zekanovic, Rajko Kusec
Introduction: Blood plasma represents a large reservoir of cytokines and other mediators of inflammation. Higher estimated plasma volume status (ePVS) has been shown to correlate with increased thrombotic risk in polycythemia vera patients, but its clinical and prognostic associations in patients with myelofibrosis are unknown which we aim to evaluate in this study.
Materials and methods: We retrospectively analysed a multicentric cohort of 238 patients with primary (PMF) and secondary myelofibrosis (SMF). Estimated plasma volume status was calculated using the Strauss-derived Duarte formula. Overall survival (OS) and time to thrombosis (TTT) considering both arterial and venous thromboses were primary endpoints of interest.
Results: Median ePVS was 5.8 dL/g and it did not significantly differ between PMF and SMF patients. Patients with more advanced disease features, more pronounced inflammation and higher comorbidity burden had higher ePVS. Higher ePVS (> 5.6 dL/g) was associated with shorter OS in PMF (unadjusted hazard ratio, HR = 2.8, 95% confidence interval, CI (1.79-4.41), P < 0.001) and SMF (unadjusted HR = 2.55, 95% CI (1.1-5.71), P =0.025) and with shorter TTT in PMF (> 7 dL/g, unadjusted HR = 4.1, 95% CI (1.44-11.59), P = 0.009) patients. Associations with OS diminished in multivariate analyses after adjustments for the dynamic-international-prognostic-scoring-system (DIPSS) and myelofibrosis-secondary-to-PV-and ET-prognostic-model (MYSEC-PM), respectively. Association with TTT remained significant independently of JAK2 mutation, white blood cell count and chronic kidney disease.
Conclusions: Myelofibrosis patients with more advanced disease features and more pronounced inflammation have higher ePVS, indicative of expanded plasma volume. Higher ePVS is associated with impaired survival in PMF and SMF and higher thrombotic risk in PMF patients.
血浆是细胞因子和其他炎症介质的大储存库。较高的估计血浆容量状态(ePVS)已被证明与真性红细胞增多症患者血栓形成风险增加相关,但其在骨髓纤维化患者中的临床和预后相关性尚不清楚,我们在本研究中旨在评估这一点。材料和方法:我们回顾性分析了238例原发性(PMF)和继发性骨髓纤维化(SMF)患者的多中心队列。估计血浆容量状态使用斯特劳斯-卡恩导出的Duarte公式计算。考虑到动脉和静脉血栓形成的总生存期(OS)和血栓形成时间(TTT)是主要的研究终点。结果:中位ePVS为5.8 dL/g, PMF和SMF患者之间无显著差异。疾病特征越晚期、炎症越明显、合并症负担越重的患者ePVS较高。较高的ePVS (> 5.6 dL/g)与PMF(未校正的风险比,HR = 2.8, 95%可信区间,CI (1.79-4.41), P < 0.001)和SMF(未校正的HR = 2.55, 95% CI (1.1-5.71), P =0.025)患者较短的OS相关,与PMF (> 7 dL/g,未校正的HR = 4.1, 95% CI (1.44-11.59), P = 0.009)患者较短的TTT相关。在调整动态国际预后评分系统(DIPSS)和骨髓纤维化继发于pv和et预后模型(MYSEC-PM)后,多变量分析中与OS的关联减弱。TTT与JAK2突变、白细胞计数和慢性肾脏疾病无关。结论:具有更晚期疾病特征和更明显炎症的骨髓纤维化患者具有更高的ePVS,表明血浆容量扩大。较高的ePVS与PMF和SMF患者的生存受损以及PMF患者较高的血栓形成风险相关。
{"title":"Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis.","authors":"Marko Lucijanic, Ivan Krecak, Ena Soric, Anica Sabljic, Davor Galusic, Hrvoje Holik, Vlatka Perisa, Martina Moric Peric, Ivan Zekanovic, Rajko Kusec","doi":"10.11613/BM.2023.020901","DOIUrl":"https://doi.org/10.11613/BM.2023.020901","url":null,"abstract":"<p><strong>Introduction: </strong>Blood plasma represents a large reservoir of cytokines and other mediators of inflammation. Higher estimated plasma volume status (ePVS) has been shown to correlate with increased thrombotic risk in polycythemia vera patients, but its clinical and prognostic associations in patients with myelofibrosis are unknown which we aim to evaluate in this study.</p><p><strong>Materials and methods: </strong>We retrospectively analysed a multicentric cohort of 238 patients with primary (PMF) and secondary myelofibrosis (SMF). Estimated plasma volume status was calculated using the Strauss-derived Duarte formula. Overall survival (OS) and time to thrombosis (TTT) considering both arterial and venous thromboses were primary endpoints of interest.</p><p><strong>Results: </strong>Median ePVS was 5.8 dL/g and it did not significantly differ between PMF and SMF patients. Patients with more advanced disease features, more pronounced inflammation and higher comorbidity burden had higher ePVS. Higher ePVS (> 5.6 dL/g) was associated with shorter OS in PMF (unadjusted hazard ratio, HR = 2.8, 95% confidence interval, CI (1.79-4.41), P < 0.001) and SMF (unadjusted HR = 2.55, 95% CI (1.1-5.71), P =0.025) and with shorter TTT in PMF (> 7 dL/g, unadjusted HR = 4.1, 95% CI (1.44-11.59), P = 0.009) patients. Associations with OS diminished in multivariate analyses after adjustments for the dynamic-international-prognostic-scoring-system (DIPSS) and myelofibrosis-secondary-to-PV-and ET-prognostic-model (MYSEC-PM), respectively. Association with TTT remained significant independently of JAK2 mutation, white blood cell count and chronic kidney disease.</p><p><strong>Conclusions: </strong>Myelofibrosis patients with more advanced disease features and more pronounced inflammation have higher ePVS, indicative of expanded plasma volume. Higher ePVS is associated with impaired survival in PMF and SMF and higher thrombotic risk in PMF patients.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"33 2","pages":"020901"},"PeriodicalIF":3.3,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}